SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is highly active following its Q4 earnings report, which presented mixed results but included strong full-year 2026 guidance. This has intensified community debate, with bulls highlighting potential short-squeeze catalysts and long-term growth, while bears emphasize slowing sequential growth and persistent regulatory and legal challenges.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is experiencing strong investor interest following a major partnership with Astellas Pharma for its VIR-5500 prostate cancer treatment, featuring significant upfront payments, profit-sharing, and substantial milestones, bolstered by positive early clinical data. The community is actively discussing the company's robust financial runway into 2028, high short interest, and upcoming ASCO GU presentation, driving expectations for continued momentum.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending amidst a sharp sell-off, driven by Anthropic's new Claude Code tool for COBOL modernization, which has ignited a debate between those fearing severe disruption to IBM's legacy consulting and mainframe revenues and others who view the market's reaction as an overreaction, highlighting IBM's established AI partnerships and robust hybrid cloud and quantum computing strengths.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as a high-stakes bidding war for Warner Bros. Discovery intensifies, with Paramount Skydance submitting a higher offer amidst political pressure from a DOJ antitrust probe and calls for a board member's removal. The community is sharply divided on whether Netflix should risk overpaying or walk away, take the breakup fee, and refocus on internal growth and buybacks.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending as the cybersecurity sector faces a significant sell-off, driven by investor fears that Anthropic's new Claude Code Security tool threatens established software business models. While many in the community debate if this is an overreaction given CRWD's distinct enterprise security offerings, concerns persist about AI's broader disruptive potential on highly valued software companies.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following strong Q4 earnings and significant international approvals for its Anktiva cancer therapy. The community is actively debating a potential short squeeze amidst high short interest, while eagerly anticipating further news and Dr. Patrick Soon-Shiong's engagements in Washington D.C. that could highlight the drug's broad impact on cancer treatment.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security is trending following strong financial results and major contract wins, including selection for the U.S. Department of War's Drone Dominance Program and a significant new verbal program award, fueling community excitement about its leadership in unmanned systems and hypersonics amid increasing global defense priorities.

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Protara Therapeutics is trending due to recent interim Phase 2 data for its TARA-002 bladder cancer and lymphatic malformations treatments, which showed strong 6-month complete response rates but sparked mixed community reactions concerning 12-month durability. Investors are actively debating the data's interpretation, its implications for future regulatory pathways, and the impact of a recent public stock offering.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is at the center of a heightened takeover battle as Paramount Skydance reportedly ups its offer, prompting widespread speculation among the community about Netflix's next move, financial sustainability, and the critical role of regulatory approval in this media consolidation saga.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx (ACLX) is trending due to Gilead Sciences' announcement of a definitive agreement to acquire the biotech for up to $7.8 billion, including a significant premium and a contingent value right, affirming the value of its CAR-T therapy, anito-cel, for multiple myeloma. The community is actively celebrating the substantial stock surge and discussing the broader implications for valuations within the innovative cell therapy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NTLA when do you think the FDA could lift the hold for MAGNITUDE Phase 3 trial for ATTR-CM?

Robotics Nuclear SMRs CRISPR

StockTwits Web

Intellia Therapeutics Inc

 when do you think the FDA could lift the hold for MAGNITUDE Phase 3 trial for ATTR-CM?

Novavax Inc

Oncolytics Biotech, Inc.

SELLAS Life Sciences Group Inc

Sarepta Therapeutics Inc

Anavex Life Sciences Corp

NuCana plc

BioXcel Therapeutics Inc

Hoth Therapeutics Inc

Kelly Mone

StockTwits for iOS

Boeing Co

GE Aerospace

Rolls-Royce Holding PLC (ADR)

NuScale Power Corp

Caribou Biosciences Inc

Oklo Inc.

GE Vernova Inc.

@3DBuilds if I&#39;m not wrong, there are two trials: one has been cleared, the other one is still waiting.

StockTwits For Android 

 if I'm not wrong, there are two trials: one has been cleared, the other one is still waiting.

@kellymone2  your right ……What Has Been Resolved
 • The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial, which tests nex-z in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This means that MAGNITUDE-2 can now resume patient enrollment and dosing with enhanced safety-monitoring measures agreed with the FDA.  ￼

❗ What Still Remains on Hold
 • The original MAGNITUDE Phase 3 trial — which is studying the same therapy for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) — remains on clinical hold pending further review and discussions with the FDA.  ￼

  your right ……What Has Been Resolved
 • The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial, which tests nex-z in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This means that MAGNITUDE-2 can now resume patient enrollment and dosing with enhanced safety-monitoring measures agreed with the FDA.  ￼

❗ What Still Remains on Hold
 • The original MAGNITUDE Phase 3 trial — which is studying the same therapy for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) — remains on clinical hold pending further review and discussions with the FDA.  ￼

@3DBuilds thanks for the info. If I remember correctly, this trial is a bit more complicated because the population is wider and the death occured here, even tho it might be unrelated to the trial itself. Let&#39; see if someone can help us with more info!

 thanks for the info. If I remember correctly, this trial is a bit more complicated because the population is wider and the death occured here, even tho it might be unrelated to the trial itself. Let' see if someone can help us with more info!